Positional advantages of supine MRI for diagnosis prior to breast‑conserving surgery.
breast cancer
supine MRI
surgical margin
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
07
11
2022
accepted:
21
12
2022
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
The present study aimed to evaluate the rate of positive surgical margins for magnetic resonance imaging (MRI) performed in the supine position prior to breast-conserving surgery (BCS). The rate of positive surgical margins and the clinicopathological factors were examined in consecutive patients with BCS who underwent preoperative MRI performed in the supine position at Sapporo Medical University Hospital (Sapporo, Japan) and related hospitals and clinics between January 2012 and December 2013. Of 1,175 eligible patients, 1,150 were included after excluding 25 patients with either bilateral breast cancer or stage IV disease. Positive margin was defined as no cancer seen on the resected margin. The primary endpoint was the rate of positive surgical margins when preoperative MRI was performed in the supine position and the secondary endpoint was identification of the factors that predict positive margins. Of the 1,150 female patients (median age, 55 years; range, 29-97 years) who underwent BCS for breast cancer following MRI performed in the supine position, 215 (18.8%) had positive margins, which is similar to the rate with MRI in the prone position, and 930 (81.2%) had negative margins. The rate of positive surgical margins in patients of the human epidermal growth factor receptor 2 (HER2) type was significantly higher than that in the non-HER2 type group (6.5 and 2.9%; χ
Identifiants
pubmed: 37090744
doi: 10.3892/mco.2023.2640
pii: MCO-18-5-02640
pmc: PMC10119546
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Breast Cancer Res Treat. 2017 Sep;165(2):273-283
pubmed: 28589366
Ann Surg. 2017 Jul;266(1):29-35
pubmed: 28257326
Eur J Cancer. 2011 Apr;47(6):879-86
pubmed: 21195605
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Breast Cancer. 2019 Jul;26(4):428-445
pubmed: 30604398
Lancet. 2010 Feb 13;375(9714):563-71
pubmed: 20159292
Eur J Surg Oncol. 2018 Nov;44(11):1725-1735
pubmed: 30120037
J Am Coll Surg. 2008 Jul;207(1):62-8
pubmed: 18589363
Ann Surg Oncol. 2010 Oct;17 Suppl 3:255-62
pubmed: 20853043
Clin Breast Cancer. 2017 Jun;17(3):e127-e134
pubmed: 28111130
Eur Radiol. 2019 Dec;29(12):7000-7008
pubmed: 31187220
J Clin Oncol. 2019 Apr 10;37(11):885-892
pubmed: 30811290
J Breast Cancer. 2019 Aug 21;22(3):453-463
pubmed: 31598344
Ann Surg Oncol. 2019 Dec;26(13):4256-4263
pubmed: 31429019
Clin Breast Cancer. 2014 Feb;14(1):40-5
pubmed: 24169374
Breast Cancer. 2009;16(3):223-8
pubmed: 19205832
Ann Surg Oncol. 2014 Oct;21(11):3473-80
pubmed: 24912611
Ann Surg. 2013 Feb;257(2):249-55
pubmed: 23187751
J Clin Oncol. 1996 Aug;14(8):2197-205
pubmed: 8708708